OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Hematology & Oncology is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	554
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	544
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	534
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	533
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	499
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	474
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial	432
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	383
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	359
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	357
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast	331
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	311
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	308
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation	304
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	300
Cancer vaccines: current status and future directions	283
Landscape of biallelic DNMT3A mutant myeloid neoplasms	278
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	278
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	274
Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma	246
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	242
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	238
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	233
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	232
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	212

Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	209
Recent advances in therapeutic strategies for non-small cell lung cancer	204
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	190
Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response	188
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	181
Personalized nanovaccines for treating solid cancer metastases	181
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	177
Ferroptosis: principles and significance in health and disease	174
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	172
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	165
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	162
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	162
Targeting CD47 for cancer immunotherapy	160
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	157
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	154
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	153
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer	151
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	146
3D chromatin architecture and transcription regulation in cancer	146
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	144
Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1	139
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology	137
Recent advances in targeted strategies for triple-negative breast cancer	130
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	129
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	129
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	128
Small RNA modifications: regulatory molecules and potential applications	126
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	124
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	123
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers	121
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	119
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?	118
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	118
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	117
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	117
COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study	117
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	116
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects	116
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	115
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	114
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	112
A single-cell and spatially resolved atlas of human osteosarcomas	110
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies	110
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting	110
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	109
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	108
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma	106
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	106
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target	106
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	105

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure	103
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth	99
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	98
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	97
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	97
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	97
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	96
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	95
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	95
HLA alleles associated with asparaginase hypersensitivity in Chinese children	95
The functional and clinical roles of liquid biopsy in patient-derived models	90
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer	90
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	89
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	89
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies	89
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer	87
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	86
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting	86
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function	86
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia	86
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial	85
LncRNA Snhg6 regulates the differentiation of MDSCs by regulating the ubiquitination of EZH2	84
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II	84
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis	80
Worked to the bone: antibody-based conditioning as the future of transplant biology	79
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy	79
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives	78
The roles of GTPase-activating proteins in regulated cell death and tumor immunity	76
Echinomycin as a promising therapeutic agent against KSHV-related malignancies	75
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting	75
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination	72
The long and short non-coding RNAs modulating EZH2 signaling in cancer	72
Challenges and new technologies in adoptive cell therapy	71
Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma	71
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives	70
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes	70
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	69
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	68
Gastric cancer treatment: recent progress and future perspectives	68
Targeting GPRC5D for multiple myeloma therapy	67
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma	66
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	66
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders	65
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies	64
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	64
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	64
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	64
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	63
Mesenchymal stem/stromal cells in cancer therapy	62
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	62
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses	62
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer	62
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	61
Metabolic reprogramming in the tumor microenvironment of liver cancer	60
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	60
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia	59
Correction: Immunosenescence: a key player in cancer development	59
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	59
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	58
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	58
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	57
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	57
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer	56
Momelotinib: an emerging treatment for myelofibrosis patients with anemia	56
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	55
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	54
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy	54
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	54
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	54
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial	53
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	52
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	52
Advances in targeting histone deacetylase for treatment of solid tumors	52
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	52
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer	52